US7613301099 - Common Stock
12.09 -0.33 (-2.66%)
After market: 12.09 0 (0%)
REVANCE THERAPEUTICS INC
NASDAQ:RVNC (9/27/2023, 7:00:02 PM)After market: 12.09 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 534 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings. The Company’s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company’s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
REVANCE THERAPEUTICS INC
1222 Demonbreun Street, Suite 2000
Nashville TENNESSEE 37203
CEO: Mark J. Foley
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
The company is still figuring out how to gain share in a market topped by AbbVie.
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Here you can normally see the latest stock twits on RVNC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.